1. Home
  2. PIII vs AKTX Comparison

PIII vs AKTX Comparison

Compare PIII & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PIII
  • AKTX
  • Stock Information
  • Founded
  • PIII 2015
  • AKTX N/A
  • Country
  • PIII United States
  • AKTX United States
  • Employees
  • PIII N/A
  • AKTX N/A
  • Industry
  • PIII Medical/Nursing Services
  • AKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • PIII Health Care
  • AKTX Health Care
  • Exchange
  • PIII Nasdaq
  • AKTX Nasdaq
  • Market Cap
  • PIII 32.2M
  • AKTX 32.8M
  • IPO Year
  • PIII N/A
  • AKTX N/A
  • Fundamental
  • Price
  • PIII $0.20
  • AKTX $1.06
  • Analyst Decision
  • PIII Buy
  • AKTX
  • Analyst Count
  • PIII 3
  • AKTX 0
  • Target Price
  • PIII $2.38
  • AKTX N/A
  • AVG Volume (30 Days)
  • PIII 5.1M
  • AKTX 26.0K
  • Earning Date
  • PIII 03-27-2025
  • AKTX 02-15-2025
  • Dividend Yield
  • PIII N/A
  • AKTX N/A
  • EPS Growth
  • PIII N/A
  • AKTX N/A
  • EPS
  • PIII N/A
  • AKTX N/A
  • Revenue
  • PIII $1,476,630,000.00
  • AKTX N/A
  • Revenue This Year
  • PIII $21.45
  • AKTX N/A
  • Revenue Next Year
  • PIII N/A
  • AKTX N/A
  • P/E Ratio
  • PIII N/A
  • AKTX N/A
  • Revenue Growth
  • PIII 25.38
  • AKTX N/A
  • 52 Week Low
  • PIII $0.17
  • AKTX $0.90
  • 52 Week High
  • PIII $1.22
  • AKTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • PIII 45.85
  • AKTX 43.41
  • Support Level
  • PIII $0.18
  • AKTX $1.10
  • Resistance Level
  • PIII $0.21
  • AKTX $1.33
  • Average True Range (ATR)
  • PIII 0.02
  • AKTX 0.15
  • MACD
  • PIII 0.00
  • AKTX -0.01
  • Stochastic Oscillator
  • PIII 56.59
  • AKTX 9.23

About PIII P3 Health Partners Inc.

P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).

Share on Social Networks: